NovaSight
NovaSight is an Israeli medical technology company developing FDA-cleared, eye-tracking-based digital therapies for pediatric vision care. Its flagship CureSight system treats amblyopia in children aged 4-9 via dichoptic streamed content, with a TrackSight SaaS pipeline targeting myopia prevention.
- Company typePrivate
- Founded2016
- HeadquartersTel Aviv, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NovaSight does
NovaSight Ltd. is an Israeli medical technology company developing eye-tracking-based digital solutions for pediatric vision care. Founded in 2016 and headquartered in Airport City, Israel, with a US office in Lewes, Delaware, the company targets two large unmet needs: amblyopia (lazy eye), which affects approximately 3% of children globally, and pediatric myopia prevention linked to excessive screen time. The flagship commercial product, CureSight, is an FDA 510(k)-cleared (K213615) and CE-marked digital therapy that treats amblyopia in children aged 4-9 by tracking eye gaze 90 times per second via optical image sensors and presenting dichoptic images through red-blue anaglyph glasses while patients watch streamed content (Netflix, YouTube, Disney+). The pipeline includes TrackSight, a SaaS solution using embedded webcams for myopia prevention, which is not yet approved for sale in any country.
The technology platform rests on proprietary eye-tracking hardware—including ActiveSight LCD Active Shutter Glasses designed for children and the EyeSwift PRO diagnostic system—combined with cloud-connected software that performs real-time dichoptic image processing. NovaSight's pivotal trial demonstrated that 79% of CureSight patients achieved 2+ line visual acuity improvement versus 61% for patching (p<0.05) in a 103-patient study across six medical centers, with 93% adherence and 95% parental preference. The company operates a US-based CureSight Monitoring Center directed by practicing ophthalmologists that handles patient onboarding, device logistics, compliance monitoring, technical support, billing, and prior authorization support, with infrastructure support from partner Notal Vision.
NovaSight's business model combines device provision with subscription-style recurring revenue billed through three unique Category III CPT codes (0704T for device setup, 0705T for monthly surveillance, 0706T for physician interpretation) assigned by the American Medical Association. CureSight is prescribed exclusively through eye care providers (ophthalmologists and optometrists) via a dedicated web portal and referral program, with reimbursement currently secured through Anthem Blue Cross Blue Shield (since April 2025) and Aetna (since July 2025). The company has raised $8 million in Series A financing (July 2020) plus $1 million in grants from the Israel Innovation Authority, and distributes its vision assessment technology internationally through a partnership with Essilor.
NovaSight firmographics
Firmographics- Name
- NovaSight
- Legal name
- NovaSight Ltd.
- Website
- https://nova-sight.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NovaSight is an Israeli medical technology company developing FDA-cleared, eye-tracking-based digital therapies for pediatric vision care. Its flagship CureSight system treats amblyopia in children aged 4-9 via dichoptic streamed content, with a TrackSight SaaS pipeline targeting myopia prevention.
- Ownership category
- akta.pro rank
NovaSight industry classification
Industry- Product category
- Pediatric Ophthalmology Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment) (HLAHAJAM)
- akta.pro secondary industries
- Vision Therapy & Orthoptics (HLAKAKAM), Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC), Contact Lens Specialty & Myopia Control (HLAKAKAK)
Keywords
Where NovaSight is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
NovaSight business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- CureSight Device and Monitoring (US): CureSight treatment is billed through three unique Category III CPT codes: 0704T (device supply, initial set-up and patient education), 0705T (surveillance center technical support and data transmission, each 30 days), and 0706T (interpretation and report by physician, per calendar month). The Monitoring Center bills for 0704T and 0705T; the clinic bills for 0706T. Insurance coverage is available through Anthem Blue Cross Blue Shield and Aetna for eligible patients. Treatment requires minimum 90 minutes per day, 5 days a week, over a physician-determined duration.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Device setup, monitoring, and physician interpretation billed through CPT codes |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
NovaSight product offering
Product offeringCore offering
NovaSight develops and sells the FDA-cleared CureSight digital amblyopia (lazy eye) treatment system for children aged 4-9, which uses eye-tracking-based real-time dichoptic image processing with red-blue anaglyph glasses while patients watch streamed content at home. The company also develops the TrackSight SaaS platform for myopia prevention using webcam-based eye-tracking, supported by the proprietary EyeSwift PRO diagnostic system and ActiveSight LCD shutter glasses for objective pediatric vision assessment.
Product overview
NovaSight offers integrated eye-tracking-based solutions for pediatric vision assessment and treatment. The core portfolio consists of two main products: CureSight (FDA-cleared amblyopia treatment) and TrackSight (myopia prevention, in development). CureSight uses specialized ActiveSight glasses and a dedicated Monitoring Center to deliver binocular vision therapy via streamed content, while TrackSight uses webcam-based eye-tracking on consumer devices. Both products are supported by the EyeSwift PRO diagnostic platform and a cloud-based web portal for eye care providers.
Differentiator
Problem solved
Functional benefit
Products and services
- CureSight FDA 510(k)-cleared and CE-marked eye-tracking-based digital therapy system for pediatric amblyopia (lazy eye) in children aged 4-9. Uses red-blue anaglyph glasses with any streamed content (Netflix, YouTube, Disney+) while tracking eye movement at 90Hz to deliver real-time dichoptic images that stimulate the amblyopic eye. Treatment is remotely supervised by an eye care provider and NovaSight's US Monitoring Center.
- TrackSight SaaS solution for myopia prevention and vision health monitoring that uses computer monitors' embedded webcams to perform eye-tracking and apply real-time peripheral blur based on momentary gaze position during screen time on laptops and tablets.
- ActiveSight Glasses
Quantifiable outcome
- 79% of CureSight patients achieved 2-line or more visual acuity improvement vs 61% for patching (p<0.05) at week 16 in pivotal trial
- +4 more outcomes
Companies that use NovaSight
Customer profileNamed customers6 records
Segments1 record
Ideal customer profiles1 record
NovaSight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability6 records
Feature4 records
NovaSight partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- EssilorcoreEssilor, a global leader in ophthalmic optics with market cap of around $64 billion, approximately 70,000 employees, 32 plants, and 14 distribution centers in over 100 countries, distributes NovaSight's vision assessment technology. Essilor launched NovaSight's vision assessment system at the French Ophthalmology Society (SFO) Meeting in Paris in 2019. Essilor's global distribution network provides NovaSight with broad market reach in the ophthalmic optics space.
- TobiicoreTobii is the global leader in eye tracking, operating through three business units: Tobii Dynavox (assistive technology), Tobii Pro (research equipment used by 3,500 companies and 2,500 research institutions), and Tobii Tech (volume markets including healthcare). NovaSight's partnership with Tobii leverages Tobii's eye-tracking technology for healthcare applications.
- EIT HealthcoreEIT Health is a consortium leveraging expertise of over 140 leading organizations across key areas of healthcare, chosen by the European Institute of Innovation and Technology. With a budget of 2 billion euros (partially from Horizon2020), EIT Health invests in Europe's best entrepreneurial talents for development and commercialization of smart health products. NovaSight benefits from EIT Health's pan-European network and resources for healthcare innovation.
- Notal VisioncoreNotal Vision provides the Notal Vision Monitoring Center, a full-service ophthalmic monitoring center directed by practicing ophthalmologists and supported by certified ophthalmic professionals. As a Medicare-credentialed digital healthcare provider, Notal Vision offers comprehensive patient education, training, and monitoring. NovaSight's CureSight Monitoring Center is supported by Notal Vision's infrastructure for remote patient monitoring and compliance tracking.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
NovaSight competitors and assessment
Company assessmentBroad incumbents
- HOYA Vision Care: Ophthalmic lens and vision-care incumbent with growing myopia-management presence; relevant comparator for NovaSight's planned TrackSight myopia prevention entry.
- Bausch + Lomb: Diversified ophthalmic goods and vision-care incumbent with a pediatric vision franchise; provides broad context for competitive and reimbursement dynamics facing NovaSight's specialty amblyopia therapy.
- Alcon: Global leader in ophthalmic surgical and vision-care products, including pediatric and refractive solutions; competes for physician mindshare and formulary access that NovaSight must win to scale CureSight.
- Carl Zeiss Meditec: Broad ophthalmic diagnostics and surgical device incumbent whose vision-assessment and diagnostic portfolio overlaps with NovaSight's EyeSwift PRO-based pediatric screening offering.
- CooperVision (SightGlass Vision): CooperVision's SightGlass Vision division develops pediatric myopia-control products; directly relevant TrackSight comparator targeting the same eye-care providers and myopia-prevention use case.
Direct peers
- Luminopia: Luminopia develops FDA-cleared dichoptic digital therapy for amblyopia in children, competing head-to-head with NovaSight's CureSight in the same pediatric ophthalmology/optometry channel using a similar mechanism of modified streamed content.
- Notal Vision: Operates a Medicare-credentialed ophthalmic monitoring center that underpins NovaSight's CureSight Monitoring Center; competes more broadly in remote ophthalmic monitoring services and infrastructure.
Emerging players
- RightEye: Eye-tracking-based vision and health assessment platform used in optometry and pediatrics; overlaps with NovaSight's EyeSwift PRO in objective vision screening and tracking-based diagnostics.
- Treehouse Eyes: US specialty provider network focused on children's myopia management; a relevant commercial-channel comparator for NovaSight's TrackSight go-to-market into pediatric eye-care practices.
- Adaptica: Developer of portable ophthalmic diagnostic devices including pediatric vision screening tools; comparable to NovaSight's EyeSwift PRO-based objective pediatric assessment offering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
NovaSight social profiles
Digital presenceNovaSight compliance and trust
Trust signalCompliance4 records
NovaSight financial estimates
Financial estimateRevenue estimate
Valuation estimate
NovaSight leadership team
Management profileNumber of profiles
Profiles6 records
NovaSight funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NovaSight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NovaSight
What does NovaSight do?
NovaSight develops and sells the FDA-cleared CureSight digital amblyopia (lazy eye) treatment system for children aged 4-9, which uses eye-tracking-based real-time dichoptic image processing with red-blue anaglyph glasses while patients watch streamed content at home. The company also develops the TrackSight SaaS platform for myopia prevention using webcam-based eye-tracking, supported by the proprietary EyeSwift PRO diagnostic system and ActiveSight LCD shutter glasses for objective pediatric vision assessment.
Is NovaSight a public or private company?
NovaSight is a private company. It is classified as venture growth investor backed and is currently operating.
When was NovaSight founded?
NovaSight was founded in 2016. It employs 11 to 50 people.
Where is NovaSight based?
NovaSight is headquartered in Tel Aviv, Israel, in the Middle East region.
How does NovaSight make money?
One revenue line is on record: cureSight Device and Monitoring (US).
Who are NovaSight's main competitors?
Broad incumbents on record are HOYA Vision Care, Bausch + Lomb, Alcon, Carl Zeiss Meditec and CooperVision (SightGlass Vision). Direct peers are Luminopia and Notal Vision. Emerging players are RightEye, Treehouse Eyes and Adaptica.
Does NovaSight have an API?
No public API is recorded for NovaSight.
What industry is NovaSight in?
NovaSight's product category is Pediatric Ophthalmology Medical Devices. Its primary akta.pro industry code is HLAHAJAM, Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment), with a secondary code of HLAKAKAM, Vision Therapy & Orthoptics. Its NAICS code is 339115 and its SIC code is 3851.